Contrast Media Market Size, Share and Global Trend By Type (Barium-based Contrast Media, Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media), By Route of Administration (Oral, Rectal, Intravenous, Ureteral), By Application (Oncology, Cardiology, Neurology), By Modality (X-ray/CT, MRI, Ultrasound), By End User (Hospitals, Clinics), and Regional Forecast, 2024-2032

A contrast agent referred to as contrast medium, is a substance used to increase the contrast of structures of fluids in the body during medical imaging. Contrast agents enhance the visibility of the targeted tissues, structures or blood vessels. Contrast agents alter or absorb external electromagnetism or ultrasound, which further emits radiation themselves. Barium-based contrast media, iodinated contrast media, gadolinium-based contrast media and microbubble contrast media are generally used contrast agents during MRI and ultrasound. Increasing prevalence of cancer, neurological and cardiovascular diseases, growing partnerships and acquisition among players to launch new products, and emerging innovations in contrast media are some of the factors likely to boost the global contrast media market during the forecast period.

Growing demand for image-guided diagnostics and procedures, increasing incidence & prevalence of cardiac diseases, and cancer, technological advancements in medical imaging techniques are some of the major driving the growth of contrast media market during the forecast period.

To gain extensive insights into the market, Request for Customization

However, due to the side effects associated while using contrast media such as stomach cramps, vomiting, bluish skin color etc., and high cost of the contrast media injectors are some of the factors restraining the growth of the global contrast media market during the forecast period.

Key Players Covered

Some of the major companies operating in the global contrast media market are AMAG Pharmaceuticals, Bayer AG, Bracco Diagnostic Inc., DAIICHI SANKYO COMPANY, LIMITED., GENERAL ELECTRIC COMPANY, Lantheus Medical Imaging, Inc., Guerbet, Nanoscan Imaging LLC, SANOCHEMIA Pharmazeutika AG, Spago Nanomedical AB., Interpharma Praha, a.s., among others.

SEGMENTATION

Among the route of administration segment, the intravenous segment is anticipated to hold the largest market share during the forecast period as they are the most commonly used route of administration and helps in enhancing the imaging which can be by delineating the surrounding structures while planning the treatment of abdominal and lower esophageal cancers.

Key Insights

• Overview of Innovations in Contrast Media
• Epidemiology Analysis of Chronic Disease/cancer
• The Regulatory Scenario of Key Countries/Regions
• Recent Key Industry Developments – Mergers, Acquisitions, And Partnerships.

Regional Analysis

Geographically, the global contrast media market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa., North America is anticipated to dominate the contrast media market during the forecast period owing to the presence of well-established healthcare infrastructure, and growing investments in research activities by many key players to develop effective contrast media agents. In addition, growing advancements in diagnostic imaging technology, the growing incidence of cancer, and cardiac disorders are likely to drive the growth of the contrast media market in North America during the forecast period. The global contrast media market in Europe and Asia Pacific region is likely to expand at significant CAGR due to increasing application of MRI procedures in cardiovascular diseases, presence of advanced cath-labs and growing prevalence of cardiac disorders.

Key Industry Developments

• In January 2018, NanoHybrids, Inc., launched PAtrace a contrast agent which is a liposomal nanoparticle encasing a biocompatible optical absorber which was designed for the use with photoacoustic (PA) imaging systems and produces depth-resolved 3D mapping of tumor permeability and retention without requiring significant preparation time.
• In December 2018, Bracco Diagnostic Inc., collaborated with the Duke University School of Medicine (Durham, North Carolina, U.S.) to improve patient care in Computed Tomography imaging that by developing advanced contrast enhanced CT imaging technologies and new software based solutions that will help in enhancing the workflow of radiologist and improve the quality care of the patient.
• In November 2018, Guerbet launched its new version of Contrast & Care, a digital contrast media injection management solution for medical imaging centers with the aim of improving the productivity of healthcare professionals and patient safety.
• In July 2016, Interpharma Praha, a.s., launched RALTA (iohexol) in U.S. which is a new oral contrast agent for abdominal CT scans.
• In April 2016, Bracco Diagnostic Inc., received FDA approval for the use of ultrasound contrast agent LUMASON for use in liver imaging, to improve the sensitivity and specificity of ultrasonography for the differentiation between malignant and benign focal hepatic lesions.